Cargando…

Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype

BACKGROUND: Adverse drug reactions (ADRs) are frequent occurring events that can essentially be defined as harmful or unpleasant symptoms secondary to the use of a medicinal product. ADRs involve a wide spectrum of clinical manifestations ranging from minor itching and rash to life-threatening react...

Descripción completa

Detalles Bibliográficos
Autores principales: Fonseca, Dora Janeth, Morel, Adrien, Llinás-Caballero, Kevin, Bolívar-Salazar, David, Laissue, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935440/
https://www.ncbi.nlm.nih.gov/pubmed/33688237
http://dx.doi.org/10.2147/PGPM.S289869
_version_ 1783661001554526208
author Fonseca, Dora Janeth
Morel, Adrien
Llinás-Caballero, Kevin
Bolívar-Salazar, David
Laissue, Paul
author_facet Fonseca, Dora Janeth
Morel, Adrien
Llinás-Caballero, Kevin
Bolívar-Salazar, David
Laissue, Paul
author_sort Fonseca, Dora Janeth
collection PubMed
description BACKGROUND: Adverse drug reactions (ADRs) are frequent occurring events that can essentially be defined as harmful or unpleasant symptoms secondary to the use of a medicinal product. ADRs involve a wide spectrum of clinical manifestations ranging from minor itching and rash to life-threatening reactions. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare ADRs. SJS-TEN may be considered a polygenic pathology due to additive/epistatic effects caused by sequence variants in numerous genes. Next-generation sequencing (NGS) represents a potentially interesting exploration tool in such scenario as it facilitates the simultaneous analysis of large genomic regions and genes at affordable cost. METHODS: The present study has involved using whole-exome sequencing (WES) for the first time on SJS-TEN patients. It involved robust and innovative multistep bioinformatics analysis focusing on 313 candidate genes potentially participating in the disease’s aetiology, specific drugs’ metabolism and gene regulation. RESULTS: We identified combinations of frequently occurring and rare variants that may contribute to the disease’s pathogenesis. Depending on the specific drug being taken, different variants (and alleles) in NAT2, CYP2D8, CYP2B6, ABCC2, UGT2B7 and TCF3 were identified as coherent candidates representing potential future markers for SJS-TEN. CONCLUSION: The present study proposed and has described (for the first time) a large-scale genomic analysis of patients affected by SJS-TEN. The genes and variants identified represent relevant candidates potentially participating in the disease’s pathogenesis. Corroborating that proposed by others, we found that complex combinations of frequently occurring and rare variants participating in particular drug metabolism molecular cascades could be associated with the phenotype. TCF3 TF may be considered a coherent candidate for SJS-TEN that should be analysed in new cohorts of patients having ADRs.
format Online
Article
Text
id pubmed-7935440
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79354402021-03-08 Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype Fonseca, Dora Janeth Morel, Adrien Llinás-Caballero, Kevin Bolívar-Salazar, David Laissue, Paul Pharmgenomics Pers Med Original Research BACKGROUND: Adverse drug reactions (ADRs) are frequent occurring events that can essentially be defined as harmful or unpleasant symptoms secondary to the use of a medicinal product. ADRs involve a wide spectrum of clinical manifestations ranging from minor itching and rash to life-threatening reactions. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare ADRs. SJS-TEN may be considered a polygenic pathology due to additive/epistatic effects caused by sequence variants in numerous genes. Next-generation sequencing (NGS) represents a potentially interesting exploration tool in such scenario as it facilitates the simultaneous analysis of large genomic regions and genes at affordable cost. METHODS: The present study has involved using whole-exome sequencing (WES) for the first time on SJS-TEN patients. It involved robust and innovative multistep bioinformatics analysis focusing on 313 candidate genes potentially participating in the disease’s aetiology, specific drugs’ metabolism and gene regulation. RESULTS: We identified combinations of frequently occurring and rare variants that may contribute to the disease’s pathogenesis. Depending on the specific drug being taken, different variants (and alleles) in NAT2, CYP2D8, CYP2B6, ABCC2, UGT2B7 and TCF3 were identified as coherent candidates representing potential future markers for SJS-TEN. CONCLUSION: The present study proposed and has described (for the first time) a large-scale genomic analysis of patients affected by SJS-TEN. The genes and variants identified represent relevant candidates potentially participating in the disease’s pathogenesis. Corroborating that proposed by others, we found that complex combinations of frequently occurring and rare variants participating in particular drug metabolism molecular cascades could be associated with the phenotype. TCF3 TF may be considered a coherent candidate for SJS-TEN that should be analysed in new cohorts of patients having ADRs. Dove 2021-03-01 /pmc/articles/PMC7935440/ /pubmed/33688237 http://dx.doi.org/10.2147/PGPM.S289869 Text en © 2021 Fonseca et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Fonseca, Dora Janeth
Morel, Adrien
Llinás-Caballero, Kevin
Bolívar-Salazar, David
Laissue, Paul
Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype
title Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype
title_full Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype
title_fullStr Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype
title_full_unstemmed Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype
title_short Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype
title_sort whole-exome sequencing in patients affected by stevens-johnson syndrome and toxic epidermal necrolysis reveals new variants potentially contributing to the phenotype
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935440/
https://www.ncbi.nlm.nih.gov/pubmed/33688237
http://dx.doi.org/10.2147/PGPM.S289869
work_keys_str_mv AT fonsecadorajaneth wholeexomesequencinginpatientsaffectedbystevensjohnsonsyndromeandtoxicepidermalnecrolysisrevealsnewvariantspotentiallycontributingtothephenotype
AT moreladrien wholeexomesequencinginpatientsaffectedbystevensjohnsonsyndromeandtoxicepidermalnecrolysisrevealsnewvariantspotentiallycontributingtothephenotype
AT llinascaballerokevin wholeexomesequencinginpatientsaffectedbystevensjohnsonsyndromeandtoxicepidermalnecrolysisrevealsnewvariantspotentiallycontributingtothephenotype
AT bolivarsalazardavid wholeexomesequencinginpatientsaffectedbystevensjohnsonsyndromeandtoxicepidermalnecrolysisrevealsnewvariantspotentiallycontributingtothephenotype
AT laissuepaul wholeexomesequencinginpatientsaffectedbystevensjohnsonsyndromeandtoxicepidermalnecrolysisrevealsnewvariantspotentiallycontributingtothephenotype